Lori Youmshajekian June 09, 2023 The US Food and Drug Administration (FDA) has approved the first waterless cyclosporine-based solution for treating the signs and symptoms of dry eye disease, according to manufacturer Novaliq GmbH. The treatment, Vevye, (topical cyclosporine ophthalmic solution, also formerly known as CyclASol) 0.1%, is a calcineurin inhibitor immunosuppressant. The water-free and nonpreserved solution contains cyclosporine 0.1%, as well as perfluorobutylpentane...